Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Shah, J.; Shacham, S.; Kauffman, M.; Daniele, P.; Tomaras, D.; Tremblay, G.; ... ; Albendea, M.A.C. (2021)

Article / Letter to editor

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p <= 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.Lay abstractThis work examined quality of life (QoL) among patients with relapsed/refractory diffuse large B-cell lymphoma with two to five prior therapies who received single-agent selinexor in the SADAL clinical trial. Analysis of patient-reported Functional Assessment of Cancer Therapy - Lymphoma and EuroQoL five-dimensions five-levels data showed that patients who had objective clinical response to selinexor maintained their QoL over the course of treatment. Grade >= 3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts.

• diffuse large B-cell lymphoma
• disutility of adverse events
• EQ-5D-5L
• FACT-Lym
• health-related quality of life
• health state utility
• health utility
• patient reported outcomes
• selinexor

• All authors: Shah, J.; Shacham, S.; Kauffman, M.; Daniele, P.; Tomaras, D.; Tremblay, G.; Casasnovas, R.O.; Maerevoet, M.; Zijlstra, J.; Follows, G.; Vermaat, J.S.P.; Kalakonda, N.; Goy, A.H.; Choquet, S.; Neste, E. van den; Hill, B.T.; Thieblemont, C.; Cavallo, F.; Cruz, F. de la; Kuruvilla, J.; Hamad, N.; Bouabdallah, R.; Jager, U.; Caimi, P.; Gurion, R.; Warzocha, K.; Bakhshi, S.; Sancho, J.M.; Schuster, M.; Egyed, M.; Offner, F.; Vasilakopoulos, T.P.; Samal, P.; Nagy, A.; Ku, M.; Albendea, M.A.C.
• Date: 2021-02-02
• Journal: Future Oncology
• Volume: 17
• Issue: 11
• Pages: 1295 - 1310
• DOI: doi:10.2217/fon-2020-0946
• Link: https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0946